Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37 |
| November 30, 2021 | November 2021 Bond Updates |
|
OSLO, Norway, Nov. 30, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be... |
| View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-rd-day-building-value-from-betalutin-and-a-pipeline-of-broader-therapeutic-opportunities-targeting-cd37-301433539.html |
| Related News |
|